Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck [abstract 6] - Senzer,N.N.; Soulieres,D.; Siu,L. (Proc Am Soc Clin Oncol, 2001)